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Abstract
The increasing incidence and emergence of multi-drug resistant (MDR) Acinetobacter baumannii has become a major global
health concern. Colistin is a historic antimicrobial that has become commonly used as a treatment for MDR A. baumannii
infections. The increase in colistin usage has been mirrored by an increase in colistin resistance. We aimed to identify the
mechanisms associated with colistin resistance in A. baumannii using multiple high-throughput-sequencing technologies,
including transposon-directed insertion site sequencing (TraDIS), RNA sequencing (RNAseq) and whole-genome sequencing
(WGS) to investigate the genotypic changes of colistin resistance in A. baumannii. Using TraDIS, we found that genes involved
in drug efflux (adeIJK), and phospholipid (mlaC, mlaF and mlaD) and lipooligosaccharide synthesis (lpxC and lpsO) were
required for survival in sub-inhibitory concentrations of colistin. Transcriptomic (RNAseq) analysis revealed that expression
of genes encoding efflux proteins (adeI, adeC, emrB, mexB and macAB) was enhanced in in vitro generated colistin-resistant
strains. WGS of these organisms identified disruptions in genes involved in lipid A (lpxC) and phospholipid synthesis (mlaA),
and in the baeS/R two-component system (TCS). We additionally found that mutations in the pmrB TCS genes were the
primary colistin-resistance-associated mechanisms in three Vietnamese clinical colistin-resistant A. baumannii strains. Our
results outline the entire range of mechanisms employed in A. baumannii for resistance against colistin, including drug
extrusion and the loss of lipid A moieties by gene disruption or modification.
DATA SUMMARY
1. The PacBio (Pacific Biosciences) sequence data and
assembly for BAL062 can be found at the European Nucleo-
tide Archive (ENA) under accession numbers: ERR581111
andERR581112, ERR581112 (www.ebi.ac.uk/ena).
2. Genome BAL062 has been deposited in GenBank under
accession numbers LT594095 (chromosome) and
LT594096 (plasmid) (url: www.ebi.ac.uk/ena/data/view/
LT594095 and www.ebi.ac.uk/ena/data/view/LT594096).
3. RNA sequencing, transposon-directed insertion site
sequencing and whole-genome sequencing data is available
at the ENA (www.ebi.ac.uk/ena) under the study accession
numbers detailed in Table S1 (available with the online ver-
sion of this article).
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INTRODUCTION
The incidence of healthcare-acquired infections caused
by multi-drug resistant (MDR) and pan-drug resistant
Acinetobacter baumannii has increased dramatically in
recent years [1]. With limited alternative treatment strat-
egies available, there has been an increasing use of the
polymyxin antimicrobial, colistin, an older generation
last-line antimicrobial that is frequently used alone or in
combination with tigecycline, carbapenems or rifampicin
[2–4]. Despite the use of combination therapy, the inci-
dence of heteroresistance and complete resistance to
colistin (colR) alone has been frequently reported in clin-
ical isolates of A. baumannii, and can result in treat-
ment failure [5, 6].
In vivo and in vitro studies of A. baumannii have iden-
tified two main genetic mechanisms for the induction of
colR: (i) lipooligosaccharide (LOS) modification through
the acquisition of single-nucleotide polymorphisms
(SNPs) in pmrAB; or (ii) the complete loss of the LOS
owing to SNPs in genes encoding lipid A biosynthesis
genes lpxA, lpxC and lpxD [7]. Alteration or loss of the
LOS results in the reduction of the net negative charge
of the LOS; thus, decreasing the affinity between colistin
and the cell membrane [8–11]. Insertion sequence (IS)
elements, such as ISAba1 and ISAba11, have also been
associated with the development of colR via the disrup-
tion of genes in the lpx gene cluster [12, 13].
Here, we aimed to gain insight into the genetic mecha-
nisms associated with colR in A. baumannii isolates
from Vietnam. This type of study is essential for cata-
loguing the various mechanisms associated with the
development of antimicrobial resistance in A. baumannii
in clinical and in vitro generated colR mechanisms. This
is particularly relevant given the different forms of colis-
tin used clinically, such as colistin methanosulphate for
therapy and colistin sulphate for selective decontamina-
tion of the gastrointestinal tract [14]. Previous studies
have utilized genomic and transcriptomic analysis of in
vivo and in vitro induced colR mutants to determine
mechanisms associated with resistance; however,
genome-wide high-throughput mutagenesis has not been
conducted. In this study, we used a colistin susceptible
(colS) A. baumannii strain (BAL062) to generate a
mutant library to assay for genes required for survival
in sub-inhibitory concentrations of colistin. Additionally,
we used a controlled directed-evolution approach to gen-
erate a colR variant from a colistin-susceptible MDR
A. baumannii isolated from a patient with ventilator-
associated pneumonia (VAP) on an adult intensive care
unit in a Vietnamese hospital to investigate the genetic
and transcriptional changes in the colR cultures [15].
We additionally performed whole-genome sequencing
(WGS) on three clinical VAP colR A. baumannii isolated
between 2012 and 2013 from the same ward to assess
the mechanisms and relation, if any, to in vitro-derived
colR A. baumannii.
METHODS
All four MDR organisms used in this study were collected
as part of a larger study investigating the aetiology of VAP
at the Hospital for Tropical Diseases in Ho Chi Minh City,
Vietnam, in 2009 [16]. These organisms, BAL062, BAL505,
BAL546 and BAL719, were isolates from bronchoalveolar
lavage (BAL). BAL062 (colS) [17] was used to generate the
transposon library and also to generate a colR variant for the
RNA sequencing (RNAseq) experiments. BAL505, BAL546
and BAL719 were all determined to be clinically colR by disc
diffusion [16] and were selected for WGS.
Susceptibility testing
Minimum inhibitory concentrations (MICs) were deter-
mined by the broth dilution method according to meth-
ods described elsewhere [18]. MICs were interpreted
according to Clinical and Laboratory Standards Institute
guidelines [19].
Inducing colistin resistance
Duplicate cultures (C1 and C2) were subjected to serial daily
passage on Mueller–Hinton (MH) agar (Oxoid) plates with
increasing concentrations (double dilutions) of colistin (1–
128mg l 1; Sigma-Aldrich) until the cultures were able to
grow in 128mg colistin l 1 (MIC >128mg l 1), i.e. ‘end-
point’. The endpoints for C1 and C2 were day 6 and day 5,
respectively. Briefly, approximately 109 c.f.u. were resus-
pended in 100 µl PBS (0.9%) and 3 µl was spotted onto agar
plates with increasing concentrations of colistin sulphate
ranging from 1 to 128mg l 1 (serial dilutions) and incu-
bated overnight at 37

C. Colonies (>20 colonies) were taken
from the plate with the highest concentration of colistin sul-
phate from each culture (C1/C2) and resuspended in 100 µl
IMPACT STATEMENT
Colistin was first introduced into the clinical field in the
late 1950s, but its use later declined due to toxicity. In
recent years, colistin has been reintroduced as a last-
line therapy in treating multi-drug resistant (MDR) Gram-
negative infections, including Acinetobacter baumannii.
The rise in colistin-resistant A. baumannii clinical strains
has been reported and the lack of new antimicrobials in
the pipeline to treat Gram-negative bacteria greatly
decreases the chance of a positive outcome in treating
MDR A. baumannii infections. We used multiple
sequence-based approaches to identify the mechanisms
behind the development of colistin resistance in A. bau-
mannii. In addition to other known mechanisms of colistin
resistance, we observed recombination events in clinical
colistin-resistant A. baumannii strains, a novel mecha-
nism that may contribute to fitness recovery. We also
highlight the use of a high-throughput mutagenesis
approach that simultaneously assays the genome for
novel candidate genes involved in colistin resistance.
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0.9% PBS, which was used to inoculate a fresh batch of
plates containing colistin. This procedure was repeated for
the duration of the experiment (5/6 days) until the defined
endpoint. At key time points, day 0 (WT), at 32mg colistin
l 1, midpoint (64mg colistin l 1) and endpoint (128mg
colistin l 1), 10 µl cell suspension was used to inoculate
10ml fresh MH broth (Oxoid) and cultures were incubated
at 37

C with agitation. RNA and DNA were extracted at
mid-log phase and after overnight incubation for RNAseq
and WGS, respectively. No 32mg colistin l 1 time point was
collected for C2, as it achieved midpoint colR after one serial
passage.
PacBio (Pacific Biosciences) sequencing of BAL062
Genomic DNA was sequenced using the PacBio RSII
sequencer (PacBio), as previously described [20]. This
yielded >65 094 individual reads with an N50 of 8.8 kb (post-
filtering), generating at least 100 coverage. De novo assem-
bly of the resulting reads was performed using HGAP.3
(PacBio). The genomes were annotated with Prokka [21]
and set to start at dnaA. The sequence data and assembly
can be found in the European Nucleotide Archive (ENA)
under accession numbers ERR581111 and ERR581112, and
(chromosome) LT594095 and (plasmid) LT594096.
WGS
DNA was sequenced on an Illumina MiSeq or HiSeq2000
(Illumina) using a method described elsewhere [22]. These
data have been deposited in the ENA (Table S1). The clini-
cal isolates were mapped onto the A. baumannii GC2
(global clone 2) 1652–2 reference genome (GenBank acces-
sion no. CP001921.1), as with previous VAP and carriage
isolates [15], to identify SNPs using a previously described
method [23]. Accession numbers for the VAP and carriage
isolates are shown in Table S2. SNPs in the pmr locus were
confirmed by Sanger sequencing (Table 3) using the primers
detailed in Table S3. Reads from the in vitro colR-generated
organism were mapped to a complete genome sequence of
BAL062. SNPs were determined as previously described
using the RedDog mapping pipeline (https://github.com/
katholt/RedDog) [15]. To identify regions disrupted by IS
elements, the BAL062 reference genome was annotated
using ISSaga (www-is.biotoul.fr/) to identify ISs for screen-
ing with ISMapper [24].
Transcriptomics and differential expression
analysis
RNA was extracted from the initial, midpoint and endpoint
C1 and C2 cultures at OD600 0.5+/ 0.05 using a modified
phenol/chloroform extraction protocol [25]. Ribosomal
RNA was depleted using a Ribo-Zero Magnetic kit (Epi-
centre Biotechnologies). The libraries were prepared using
the TruSeq Illumina protocol and sequenced on an Illumina
HiSeq2000 platform. Reads were mapped onto the BAL062
reference using SMALT v0.7.4 and the resulting mapped reads
were used for differential expression analysis, which was
performed using DESeq (v. 1.8.2) [26]. Read counts from
the colR cultures, grown in the presence (64 or 128mg l 1)
or absence of colistin, were compared to the colistin-naïve
initial culture to determine the genes with altered expression
during colR. In addition, the initial colistin-naïve culture
was compared to the BAL062 reference to remove genes
with differential expression in response to ageing on solid
media. Genes with a log2 fold-change (log2FC) of >1.5
(increased expression) or a log2FC 1.5 (decreased expres-
sion) and a q value <0.05 were considered in this analysis.
Transposon mutant library generation and
sequencing
The transposon mutant library in WT BAL062 was gener-
ated using an EZ:Tn5 transposon containing a kanamycin-
resistance cassette (Epicentre Biotechnologies), as described
previously [27]. The colony number was estimated and cells
batch pooled as described in [28] to yield a total of
600 000 cells in the library. For the experiment, approxi-
mately 1109 cells were inoculated into 10ml MH broth
containing 0.05mg colistin sulphate l 1 (1/10th MIC;
Sigma-Aldrich) and incubated overnight in a shaking incu-
bator at 37

C. The control did not contain colistin and
experimental conditions were assessed in duplicate. The cul-
ture was serially passaged, taking 100 µl and inoculating
10ml fresh broth with the same amount of colistin or none
for the control. After an overnight incubation, DNA was
extracted from 2ml culture using the Wizard genomic DNA
purification protocol (Promega) and sequenced as previ-
ously described [29].
Analysis of transposon-directed insertion site
sequencing (TraDIS) data
TraDIS sequence analysis was performed as previously
described [29, 30]. Significant differences in mutant fre-
quencies between the colistin-exposed library and the con-
trol were determined by using the edgeR package [31]. Only
genes with a fold-change (log2FC) of >2 were considered
and a corrected P value (q value, Benjamini Hochberg, of
<0.05). Table S4 shows the insertion frequency results of the
base library used in all challenge experiments.
Recombination testing
We reconstructed a phylogenetic tree (midpoint rooted) of
the colR organisms and a subset of isolates from VAP
(n=50) and asymptomatic carriage (n=16) from a previously
reported study [16] using RAxML v7.8.6 with the
GTRGAMMA model [32] and putative recombination
blocks were predicted using gubbins, as previously described
[33]. Results were viewed using Phandango (http://james-
hadfield.github.io/phandango/)[34].
RESULTS AND DISCUSSION
Intrinsic mediators of colistin resistance in A.
baumannii
We used a TraDIS screen to investigate the intrinsic
mediators of colR by exposing a colS A. baumannii
transposon library to a sub-inhibitory concentration of
colistin. High-throughput transposon mutagenesis
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methods, such as TraDIS, have been commonly used to
assay for essential genes and genes required for survival
in a given experimental condition (reviewed in [35]).
We constructed a Tn5 library in a GC2 isolate, BAL062,
from a patient with VAP. The library consisted of
>115 000 unique mutants (roughly 1 insertion every
35 bp). We sequenced the base library and identified
445 essential genes (Table S4) that had an insertion
index 0.0047, accounting for ~12% of the genome.
This base library was used in all subsequent TraDIS
experiments in the presence or absence (control) of
colistin sulphate (0.5mg l 1). Candidate genes required
for colistin tolerance (where mutants are lost under the
experimental conditions) or those whose loss is benefi-
cial in the presence of colistin (where mutants expand
under the experimental conditions) were determined as
previously described [28, 29]. We identified 22 candidate
genetic loci that were required for colistin tolerance
(Table 1). The identified loci included genes that were
directly involved in LOS synthesis (lpxO and lpsC) and
peptidoglycan synthesis (mcrB and galE), and genes
involved in transcription (sigX) and translation (rplN,
rpmA and rpsO). We also identified a glycosyl transfer-
ase, mfpsA (similar to lpsB), which has been previously
Table 1. A. baumannii genes involved in colistin tolerance identified by TraDIS
Locus tag Gene
name
Predicted function log2
FC
q value
Candidate genes involved in colistin tolerance
BAL062_00718 Hypothetical protein  4.46 5.99e 08
BAL062_00584 Glycosyltransferase, uncharacterized protein conserved in bacteria  4.36 6.56e 12
BAL062_00901 sigX RNA polymerase factor sigma-70  4.31 1.51e 07
BAL062_00589 Glycosyltransferase involved in LOS biosynthesis  3.82 1.17e 22
BAL062_03855 tuaD_1 Udg/UDP-glucose 6-dehydrogenase  3.81 2.87e 04
BAL062_03869 tuaD_2 UDP-glucose/GDP-mannose dehydrogenase  3.81 9.04e 10
BAL062_03850 manB Phosphomannomutase  3.78 4.25e 06
BAL062_00588 Hypothetical protein  3.63 5.50e 12
BAL062_00587 UDP-D-galactose: (glucosyl)lip opolysaccharide-1,6-D-galactosyltransferase, glycosyl transferases group 1  3.59 1.46e 21
BAL062_00586 lpsC Lipooligosaccharide core biosynthesis glycosyl transferase, glycosyl transferase family 2  3.59 2.07e 21
BAL062_03854 pgi Glucose-6-phosphate isomerase  3.52 6.12e 08
BAL062_03856 galU UTP-glucose-1-phosphate uridylyltransferase  3.37 3.83e 02
BAL062_03481 mfpsA Lipopolysaccharide 1,2-N-acetylglucosaminetransferase, glycosyl transferases group 1  3.34 5.86e 05
BAL062_01632 rseP Putative membrane-associated Zn-dependent proteases 1  3.29 8.93e 07
BAL062_03605 lpxO b-Hydroxylase, aspartyl/asparaginyl b-hydroxylase  3.25 3.70e 06
BAL062_03853 galE_2 UDP-glucose 4-epimerase  3.11 3.19e 29
BAL062_00384 mlaC Toluene tolerance protein (Ttg2D)/mlaC  2.79 2.93e 08
BAL062_01261 mrcB Murein polymerase, penicillin-binding protein 1B  2.77 4.92e 12
BAL062_00383 ttg2C Toluene tolerance efflux transporter (ABC superfamily)/mlaD
 2.66
2.37e 10
BAL062_00585 icaB Putative polysaccharide deacetylase, poly-b-1,6-N-acetyl-D-glucosamine N-deacetylase precursor,  2.47 1.79e 02
BAL062_00381 ttg2A Toluene tolerance efflux transporter (ABC superfamily)/mlaF  2.45 3.32e 13
Candidate genes contributing to colistin sensitivity
BAL062_03783 guaA_3 GMP synthase, GMP synthase [glutamine-hydrolysing] 5.86 6.64e 02
BAL062_03861 lst Putative polysaccharide biosynthesis protein, glycosyltransferase family 52 5.86 6.64e 02
BAL062_02787 Hypothetical protein 4.23 6.01e 03
BAL062_03154 ligA DNA ligase 3.83 4.02e 02
BAL062_00203 Putative NAD/FAD-binding protein 2.65 3.33e 05
BAL062_03033 Hypothetical protein 2.63 2.58e 02
BAL062_01328 TetR family transcriptional regulator, transcriptional regulator BetI, transcriptional repressor 2.31 6.68e 02
BAL062_01331 Protein CsuB, uncharacterized secreted protein, spore coat protein U domain 2.22 4.81e 02
BAL062_01669 Glycolate/propanediol utilization protein, hypothetical protein, domain of unknown function (DUF336) 2.17 9.73e 02
BAL062_01330 Protein CsuA, uncharacterized secreted protein 2.13 5.27e 02
BAL062_01329 Protein CsuA/B, uncharacterized secreted protein, spore coat protein U domain 2.03 2.57e 02
BAL062_01333 caf1A Protein CsuD, F1 capsule-anchoring protein precursor, fimbrial outer-membrane usher protein PefC, fimbrial
usher protein
1.93 1.32e 02
BAL062_01332 P pilus assembly protein, chaperone PapD, putative chaperone protein EcpD, Gram-negative pili assembly
chaperone, N-terminal domain
1.88 8.15e 02
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identified in transposon mutagenesis studies as being
important for LOS synthesis [36]. Notably, sigX in Bacil-
lus subtilis has been shown to be involved in modifying
the cell envelope and conferring resistance to cationic
antimicrobial peptides [37]. Additionally, a recent study
using TraDIS to investigate candidate genes involved in
colistin resistance identified multiple genes involved in
membrane biogenesis and cellular integrity as important
for colistin tolerance [38].
Candidate genes involved in maintaining cell-surface lipid
symmetry [39] were also amongst those that we identified
to be required for tolerance to colistin, including ttg2D/
mlaC, ttg2A/mlaF and ttg2C/mlaD (Table 1). Other genes
within the mla locus were just below the stringent log2FC
2 (q value <0.05) cut-off for genes required for tolerance
(Table S5). Previous studies have found that the mlaBCD
genes are upregulated in colR A. baumannii strains lacking
LOS [40] and deletion of any component of the Mla path-
way results in outer-membrane (OM) instability [39]. These
data highlight the critical role of maintaining the lipid com-
ponent and stability of the OM in colistin-susceptible
organisms in A. baumannii.
Candidate genes that were thought to contribute to colistin
susceptibility (i.e. the disruption of genes beneficial for sur-
vival in the presence of colistin) included putative pilus
assembly genes (BAL062_01329, caf1A and BAL062_01332)
and a gene encoding a TetR family protein (BAL062_01328)
with 99% DNA sequence similarity to adeN. Previous stud-
ies have reported a decrease in the expression of OM struc-
tures, such as pili, in response to disruption or damage of
the OM that may act to limit membrane spanning surface
structures to maintain cellular integrity [40]. AdeN is mem-
ber of the TetR transcriptional repressor family and has
been shown to regulate the expression of adeIJK efflux pro-
teins [41], suggesting the involvement of efflux for survival
in the presence of sub-inhibitory concentrations of colistin.
ISAbA1-mediated mlaA, lpx and baeSR gene
disruption confers resistance to colistin
To determine the genetic changes in in vitro generated colR
organisms, two independent biological replicate cultures
(C1 and C2) of A. baumannii BAL062 that achieved an
MIC of >64mg l 1 (midpoint)/ 128mg l 1 (endpoint)
were subjected to WGS (Table 2). We detected multiple
ISAbA1-mediated disruptions in the lpxC gene in the
induced colR organisms (C1 and C2) grown in media sup-
plemented with 64 and 128mg colistin l 1 (Table 2). The
lpxC gene is almost ubiquitous across Gram-negative bac-
teria and is an essential component of the lipid-A biosyn-
thesis pathway. Mutations in the lpx genes have previously
been shown to confer resistance to colistin in A. baumannii
[11–13]. We identified only two mutations in yet uncharac-
terized genes,  404 upstream of a putative OMP gene,
BAL062_00181 and BAL062_01694 (Q212*); however, the
effect of these mutations in colR or as compensatory muta-
tions requires further investigation.
We additionally observed the disruption of mlaA (a trans-
membrane protein) by ISAba1 in both the C1 and C2 colR
(128mg l 1) cultures (Table 2). MlaA is an OM lipopro-
tein of unknown function that has been previously impli-
cated in colR [39]. The disruption of mlaA by ISAba1
suggests this protein contributes toward colistin tolerance.
Mutations in this gene have also been observed previously
in colR A. baumannii [17]. However, this finding contra-
dicts the results observed using TraDIS, where mlaA inacti-
vation resulted in increased susceptibility. We hypothesize
that maintaining cellular integrity is crucial for survival at
low sub-inhibitory concentrations (as in the TraDIS experi-
ments) and may be present in a mixed population (Fig. S1);
however, once resistance is achieved (directed evolution
experiments), the disruption of LOS synthesis, mediated by
mutations in lpx, becomes the primary mechanism of resis-
tance and mlaA becomes less critical as colistin can no lon-
ger bind to the negatively charged LOS polymer due to
charge interactions. We hypothesize that this dynamic shift
in resistance mechanisms at the different concentrations of
colistin could be a novel colR mechanism employed by A.
baumannii associated with tolerance to colistin until full
resistance is achieved.
The C1 and C2 midpoint cultures grown in the presence of
64mg colistin sulphate l 1 additionally had ISAba1 disrup-
tions in baeS (C2) or baeR (C1). These loci constitute part
Table 2. ISAba1-mediated disruptions in colistin-resistant BAL062-derived
Culture Passage
day
Colistin concn
(mg l 1)
Further growth with colistin† Further growth without colistin†
C1 1 0 – None
2 32 None None
5 64 lpxC (572), mlaA (894) lpxC (572), lpxD (828), baeR (159)
6 128 lpxC (572), mlaA (894) lpxC (572), mlaA (894),  404 upstream of OMP
BAL062_00181
C2 2 64 lpxC (572), baeS (1033), BAL062_01694 (Q212*) None
5 128 lpxC (523, 270), mlaA (561), BAL062_01694
(Q212*)
lpxC (523, 270), BAL062_01694 (Q212*)
†Gene names indicate ISAba1-disrupted genes and the amino acid positions are given in brackets. Q212* is the nonsense mutation at position 212 in
BAL062_01694.
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of a two-component system (TCS) involved in bacterial
stress response and increased expression of multidrug efflux
proteins [42–44]. We subjected the C1 culture (baeR dis-
rupted) to RNAseq to investigate any changes in efflux. Sur-
prisingly, we found a ~3- and ~5-fold increase in expression
in macAB and adeABC efflux systems, respectively, in the
presence of 64mg colistin l 1 (Fig. 1, Table S6). This is an
unusual observation, and we can only hypothesize that
other TCSs not yet characterized may be responsible for this
observation. Another unexplained observation was the lack
of genotypic changes that could account for the C1 culture
able to grow in 32mg colistin l 1 (Table 2). This lack of fixa-
tion of a mutant population has previously been reported in
a heteroresistant Klebsiella pneumoniae [45]. In a recent
study, Band and colleagues [46] described a loss of colR of
an otherwise resistant population upon removal of selection,
further demonstrating the heteroresistant nature of colistin
exposure to bacterial populations. We postulate that this
phenomenon may also occur in A. baumannii, where the
SNP changes would be present in a subpopulation. How-
ever, we would need to carry out further work to confirm
this and explain the genetic basis of the would-be out-com-
petition of these mutant variants by WT variants.
Mutation in a zinc peptidase may provide an
alternative colistin-resistance mechanism
We further observed a nonsense mutation (Q212) in a zinc
peptidase (BAL062_01694) in one of the passage cultures
(C2) when grown in 64 and 128mg colistin l 1. Zinc pepti-
dases catalyse the cleavage of peptide bonds in a metal-
dependent manner [47]. The nonsense mutation in colR
organisms occurred upstream of the active site (E270), and
likely rendered this enzyme inactive. Zinc metalloproteases
have been linked in antimicrobial peptide resistance in
Fig. 1. Transcriptional changes in in vitro generated colistin-resistant A. baumannii. Differentially expressed genes common to all
colistin-resistant cultures (C1 and C2) grown in the presence of colistin (64 or 128 mg l 1) or without selection compared to the day 0
BAL062 culture (WT). The heat map, obtained using values from DESeq2 analysis, excludes genes that were differentially expressed in
the passaged BAL062 culture that was not exposed to any colistin. Blue colours indicate genes with higher expression relative to the
comparator, red colours indicate lower expression.
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Burkholderia spp. [48]. This mutation has previously been
identified in a colR BAL062 strain and is thought to be
involved in OM processing [17].
Mutations in the pmr locus confer colistin
resistance in clinical isolates of A. baumannii
We investigated mechanisms of colR in three clinical A. bau-
mannii strains. These organisms were isolated in late 2012
and early 2013 from patients treated with empirical low
dose colistin (2.3mg 1 kg 1 per day). After repeated treat-
ment failure, clinical specimens were taken and the isolates
were subjected to WGS after they were found to be resistant
to both colistin and meropenem. These three clinical iso-
lates, BAL505, BAL543 and BAL719, had MIC values of 24,
16 and 64mg colistin l 1, respectively. WGS indicated that
all three isolates belonged to GC2, but harboured a large
number of non-synonymous SNPs in pmrB relative to the
colS GC2 1652–2 reference genome.
On further investigation, we observed that the genomes of
two of the colR isolates (BAL505 and BAL543) exhibited evi-
dence of substantial recombination with other co-circulat-
ing A. baumannii of approximately 700 kb in length with a
total of 14 296 SNPs (Fig. 2)(Table S7). Recombination
events are frequently reported in the capsule and outer core
regions in MDR A. baumannii, and are thought to be an
important source of diversification [49–51]. The putative
recombinogenic region harboured the pmr locus, which
explained the high number of SNPs. We conducted a
BLASTN and BLASTP search to identify mutations that may
confer a colR phenotype. We found BAL505 harboured a
H266Y mutation in the histidine kinase domain of pmrB,
whilst BAL543 and BAL719 harboured mutations at posi-
tions L94W and P170L (Table 3). The P170L mutation has
previously been reported in a polymyxin-resistant A. bau-
mannii clinical isolate [8], the other two mutations have not
been observed previously in colR. Mutations in the pmrAB
locus have previously been shown to confer colR in A. bau-
mannii [7, 14, 52, 53].
Transcriptional analysis of in vitro generated colR
strains
We compared genes that were differentially expressed
between the two independent colR organisms in the pres-
ence and absence of colistin, midpoint and endpoint for C1
and endpoint for C2 (Tables S1 and S8). To rule out changes
in expression as a result of passaging, we compared aged
colonies to an independent culture maintained over the
same period without antimicrobial selection.
Genes with decreased expression
ColR cultures (C1 and C2) grown in either the presence (64
and 128mg l 1) or absence of colistin exhibited a decreased
expression of genes involved in metabolic processes such as
histidine utilization, i.e. hutUHI, fatty acid catabolism and
the CoA thioester intermediates (e.g. paa, echA8 and mgh)
(Table S6). The hut genes are involved in the formation of
formiminoglutamate and is an essential amino acid in pro-
tein synthesis [54, 55], whereas fatty acid catabolism is
involved in the breakdown of LOS, the primary target for
Fig. 2. Inferred recombination in clinical isolates of colistin-resistant A. baumannii. These data were visualized using Phandango
(https://github.com/jameshadfield/phandango/). (a) A maximum-likelihood tree of the clinical colistin-resistant organisms (BAL505,
BAL543 and BAL719) and colistin-sensitive A. baumannii GC strains [42]. (b) Schematic representation of the reference A. baumannii
genome. (c) Recombination regions are indicated as coloured blocks relative to the taxa involved, red blocks indicate predicted recom-
bination that occurred on an internal branch, blue blocks are only present in one isolate (I) and the genomic region affected (II). (d) The
line graph summarizes the data in (c).
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colistin [6]. We expected that the decreased expression of
these genes reduced the destructive impact of colistin expo-
sure reinforcing the cell membrane and maintaining cellu-
lar integrity.
Genes with increased expression
Differentially expressed genes between the different colR
cultures (C1 and C2) grown in the presence of colistin, at 64
or 128mg l 1, or in the absence of colistin were also com-
pared. Genes common to all four conditions (colR +/ 
colistin) and not in aged colonies (control) were considered.
A 2–11-fold (log2FC 1.5–5.8) increase in expression was
observed in genes encoding the efflux proteins adeI, adeC,
emrB, mexB/adeJ and macAB relative to the parent strain
when not exposed or grown in colistin (Fig. 1, Table S6).
Previous studies have also seen an increase in expression of
efflux proteins adeIJK and macAB-tolC in a lpx-deficient A.
baumannii strain in the presence of colistin [40]. In in our
study, adek (BAL062_00757) and tolC (BAL062_03655) did
not meet the minimum threshold (Table S8).
Notably, a transcriptional regulator nemR, which is
upstream of macAB and part of the TetR family, exhibited a
3–6-fold decrease in expression in the colR cultures, indicat-
ing that this efflux system may be under the control of
nemR, a common feature of the TetR repressors [56]. Efflux
is a collective mechanism employed by bacteria to confer
resistance to multiple drugs including colistin in A. bau-
mannii [57–59]. We hypothesize that along with the
involvement of mla in subinhibitory concentrations in the
TraDIS experiment, initial response to colistin is primarily
by efflux until lipid-A synthesis is disrupted due to the
ISAba1-mediated disruption of lpxC, where both resistance
mechanisms may function together. Further experiments
will be needed to confirm this.
Other genes with increased expression included those
encoding putative signal peptides BAL062_00353,
BAL062_00598 and BAL062_03891, an acid shock protein
(BAL062_00604), two 17 kDa surface antigens
(BAL062_01389 and BAL062_01390), and a lipoprotein
(BAL062_03623). These genes had a 4–17-fold increase in
expression. Future work is required to elucidate the function
of these genes and their role in colistin resistance/tolerance.
Conclusion
Our analysis showed that multiple mechanisms are associ-
ated with intrinsic and acquired mechanisms of colR in A.
baumannii. Genes involved in the maintenance of cellular
integrity appear to be crucial in permitting bacteria to
survive in sub-inhibitory concentrations of colistin, in addi-
tion to genes involved in peptidoglycanand LOS synthesis.
The colR mechanisms outlined above were mainly associ-
ated with ISAba1 or mutational changes in genes critical for
cell wall synthesis or genes controlling their expression.
This included the disruption of baeR, a TCS, resulting in the
increased expression of efflux pumps, such as MacAB and
AdeIJK. Drug efflux is an important resistance mechanism
in bacteria, and has recently been identified in mediating
colR in A. baumannii [60]. A recent study using an efflux
pump inhibitor found that carbonyl cyanide m-chloro-
phenyl hydrazine (CCCP) reversed and/or suppressed colR
in A. baumannii [61]. Although this chemical compound is
not suitable for clinical use, our work highlights the crucial
role of MDR efflux pumps in acquired colR, which could be
useful targets for future therapies to be used in combination
with colistin to maintain the efficacy of this crucial last-line
therapy. Our results have described the complex yet linked
nature of colistin tolerance and colR, highlighting the inter-
action of a multitude of effectors and stress-related genes
required to generate this phenotype.
Funding information
This work was supported by the Wellcome Trust grant number
WT098051. A. K. C. and C. J. B. were supported by the Medical Research
Council (grant number G1100100/1). K. E. H. is supported by the
National Health and Medical Research Council (NHMRC)of Australia
(fellowship number 1061409). S. B. is a Sir Henry Dale Fellow, jointly
funded by the Wellcome Trust and the Royal Society (100087/Z/12/Z).
D. P. T. is supported by an OAK foundation fellowship.
Acknowledgements
The authors thank David Harris and the Wellcome Trust Sanger Insti-
tutesequencing teams for coordination of sample sequencing.
Conflicts of interest
The author(s) declare that there are no conflicts of interest.
Data Bibliography
1. Sequence data (WGS and RNAseq) from this study were deposited
in the European Nucleotide Archive and the accession numbers may
be be found in Table S2.
2. The complete genome sequence for baumanniiGC2 1652-2 was
obtained from Park JY, Kim S, Kim S-M, Cha SH, Lim S-K, et al.
Complete genome sequence of multidrug resistant Acinetobacter
baumannii strain 1656-2, which forms sturdy biofilm. J Bacteriol 2011;
193:6393–4.
References
1. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN et al. Global
challenge of multidrug-resistant Acinetobacter baumannii.
Antimicrob Agents Chemother 2007;51:3471–3484.
2. Chen Z, Chen Y, Fang Y, Wang X, Chen Y et al. Meta-analysis of
colistin for the treatment of Acinetobacter baumannii infection. Sci
Rep 2015;5:17091.
3. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ,
Barrero-Almodóvar AE, García-Garmendia JL et al. Treatment of
multidrug-resistant Acinetobacter baumannii ventilator-associated
pneumonia (VAP) with intravenous colistin: a comparison with imi-
penem-susceptible VAP. Clin Infect Dis 2003;36:1111–1118.
4. Petrosillo N, Chinello P, Proietti MF, Cecchini L, Masala M et al.
Combined colistin and rifampicin therapy for carbapenem-resis-
tant Acinetobacter baumannii infections: clinical outcome and
adverse events. Clin Microbiol Infect 2005;11:682–683.
Table 3. Summary of amino acid changes identified in colistin-
resistant clinical A. baumannii isolates
Organism Amino acid changes in PmrB MIC (mg l 1)
BAL505 H266Y 24
BAL543 L94W 16
BAL719 P170L 64
Boinett et al., Microbial Genomics 2019;5
8
5. Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acine-
tobacter baumannii: clinical reports, mechanisms and antimicro-
bial strategies. J Antimicrob Chemother 2012;67:1607–1615.
6. Li J, Nation RL, Owen RJ, Wong S, Spelman D et al. Antibiograms
of multidrug-resistant clinical Acinetobacter baumannii: promising
therapeutic options for treatment of infection with colistin-resis-
tant strains. Clin Infect Dis 2007;45:594–598.
7. Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR
et al. Resistance to colistin in Acinetobacter baumannii associated
with mutations in the PmrAB two-component system. Antimicrob
Agents Chemother 2009;53:3628–3634.
8. Arroyo LA, Herrera CM, Fernandez L, Hankins JV, Trent MS et al.
The pmrCAB operon mediates polymyxin resistance in Acineto-
bacter baumannii ATCC 17978 and clinical isolates through phos-
phoethanolamine modification of lipid A. Antimicrob Agents
Chemother 2011;55:3743–3751.
9. Lee H, Hsu FF, Turk J, Groisman EA. The PmrA-regulated pmrC
gene mediates phosphoethanolamine modification of lipid A and
polymyxin resistance in Salmonella enterica. J Bacteriol 2004;186:
4124–4133.
10. Vaara M, Vaara T, Sarvas M. Decreased binding of polymyxin by
polymyxin-resistant mutants of Salmonella typhimurium. J
Bacteriol 1979;139:664–667.
11. Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E et al.
Colistin resistance in Acinetobacter baumannii is mediated by com-
plete loss of lipopolysaccharide production. Antimicrob Agents
Chemother 2010;54:4971–4977.
12. Lim TP, Ong RT, Hon PY, Hawkey J, Holt KE et al. Multiple genetic
mutations associated with polymyxin resistance in Acinetobacter
baumannii. Antimicrob Agents Chemother 2015;59:7899–7902.
13. Moffatt JH, Harper M, Adler B, Nation RL, Li J et al. Insertion
sequence ISAba11 is involved in colistin resistance and loss of
lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents
Chemother 2011;55:3022–3024.
14. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for
the management of multidrug-resistant gram-negative bacterial
infections. Clin Infect Dis 2005;40:1333–1341.
15. Schultz MB, Pham Thanh D, Tran do Hoan N, Wick RR, Ingle DJ
et al. Repeated local emergence of carbapenem-resistant Acineto-
bacter baumannii in a single hospital ward. Microb Genom 2016;2:
mgen.0.000050.
16. Nhu NTK, Lan NPH, Campbell JI, Parry CM, Thompson C et al.
Emergence of carbapenem-resistant Acinetobacter baumannii as
the major cause of ventilator-associated pneumonia in intensive
care unit patients at an infectious disease hospital in southern
Vietnam. J Med Microbiol 2014;63:1386–1394.
17. Thi Khanh Nhu N, Riordan DW, do Hoang Nhu T, Thanh DP,
Thwaites G et al. The induction and identification of novel colistin
resistance mutations in Acinetobacter baumannii and their implica-
tions. Sci Rep 2016;6:28291.
18. Andrews JM. Determination of minimum inhibitory concentra-
tions. J Antimicrob Chemother 2001;48:5–16.
19. CLSI. Performance Standards for Antimicrobial Susceptibility
Testing, M100-S20. Wayne, PA: Clinical and Laboratory Standards
Institute; 2010.
20. Boinett CJ, Harris SR, Langridge GC, Trainor EA, Merkel TJ et al.
Complete genome sequence of Bordetella pertussis D420. Genome
Announc 2015;3:e00657–15.
21. Seemann T. Prokka: rapid prokaryotic genome annotation.
Bioinformatics 2014;30:2068–2069.
22. Quail MA, Otto TD, Gu Y, Harris SR, Skelly TF et al. Optimal
enzymes for amplifying sequencing libraries. Nat Meth 2011;9:10–
11.
23. Harris SR, Feil EJ, Holden MT, Quail MA, Nickerson EK et al. Evo-
lution of MRSA during hospital transmission and intercontinental
spread. Science 2010;327:469–474.
24. Hawkey J, Hamidian M, Wick RR, Edwards DJ, Billman-Jacobe H
et al. ISMapper: identifying transposase insertion sites in bacterial
genomes from short read sequence data. BMC Genomics 2015;16:
667.
25. Vergara-Irigaray M, Fookes MC, Thomson NR, Tang CM. RNA-seq
analysis of the influence of anaerobiosis and FNR on Shigella flex-
neri. BMC Genomics 2014;15:438.
26. Anders S, Huber W. Differential expression analysis for sequence
count data. Genome Biol 2010;11:R106.
27. Hassan KA, Cain AK, Huang T, Liu Q, Elbourne LD et al. Fluores-
cence-based flow sorting in parallel with transposon insertion site
sequencing identifies multidrug efflux systems in Acinetobacter
baumannii. mBio 2016;7:e01200–16.
28. Langridge GC, Phan MD, Turner DJ, Perkins TT, Parts L et al.
Simultaneous assay of every Salmonella Typhi gene using one mil-
lion transposon mutants. Genome Res 2009;19:2308–2316.
29. Barquist L, Mayho M, Cummins C, Cain AK, Boinett CJ et al. The
TraDIS toolkit: sequencing and analysis for dense transposon
mutant libraries. Bioinformatics 2016;32:1109–1111.
30. Dembek M, Barquist L, Boinett CJ, Cain AK, Mayho M et al. High-
throughput analysis of gene essentiality and sporulation in Clos-
tridium difficile. mBio 2015;6:e02383.
31. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor
package for differential expression analysis of digital gene
expression data. Bioinformatics 2010;26:139–140.
32. Stamatakis A. RAxML-VI-HPC: maximum likelihood-based phylo-
genetic analyses with thousands of taxa and mixed models.
Bioinformatics 2006;22:2688–2690.
33. Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA et al.
Rapid phylogenetic analysis of large samples of recombinant bac-
terial whole genome sequences using Gubbins. Nucleic Acids Res
2015;43:e15–e15.
34. Hadfield J, Croucher NJ, Goater RJ, Abudahab K, Aanensen DM
et al. Phandango: an interactive viewer for bacterial population
genomics. Bioinformatics 2017;34:292–293.
35. Barquist L, Boinett CJ, Cain AK. Approaches to querying bacterial
genomes with transposon-insertion sequencing. RNA Biol 2013;10:
1161–1169.
36. Hood MI, Becker KW, Roux CM, Dunman PM, Skaar EP. Genetic
determinants of intrinsic colistin tolerance in Acinetobacter bau-
mannii. Infect Immun 2013;81:542–551.
37. Cao M, Helmann JD. The Bacillus subtilis extracytoplasmic-func-
tion sigmaX factor regulates modification of the cell envelope and
resistance to cationic antimicrobial peptides. J Bacteriol 2004;186:
1136–1146.
38. Jana B, Cain AK, Doerrler WT, Boinett CJ, Fookes MC et al. The
secondary resistome of multidrug-resistant Klebsiella pneumoniae.
Sci Rep 2017;7:42483.
39. Malinverni JC, Silhavy TJ. An ABC transport system that main-
tains lipid asymmetry in the gram-negative outer membrane. Proc
Natl Acad Sci USA 2009;106:8009–8014.
40. Henry R, Vithanage N, Harrison P, Seemann T, Coutts S et al.
Colistin-resistant, lipopolysaccharide-deficient Acinetobacter bau-
mannii responds to lipopolysaccharide loss through increased
expression of genes involved in the synthesis and transport of lip-
oproteins, phospholipids, and poly-b-1,6-N-acetylglucosamine.
Antimicrob Agents Chemother 2012;56:59–69.
41. Rosenfeld N, Bouchier C, Courvalin P, Perichon B. Expression of
the resistance-nodulation-cell division pump AdeIJK in Acineto-
bacter baumannii is regulated by AdeN, a TetR-type regulator.
Antimicrob Agents Chemother 2012;56:2504–2510.
42. Raffa RG, Raivio TL. A third envelope stress signal transduction
pathway in Escherichia coli. Mol Microbiol 2002;45:1599–1611.
43. Lin MF, Lin YY, Lan CY. The role of the two-component system
BaeSR in disposing chemicals through regulating transporter sys-
tems in Acinetobacter baumannii. PLoS One 2015;10:e0132843–15.
Boinett et al., Microbial Genomics 2019;5
9
44. Nagakubo S, Nishino K, Hirata T, Yamaguchi A. The putative
response regulator BaeR stimulates multidrug resistance of
Escherichia coli via a novel multidrug exporter system, MdtABC. J
Bacteriol 2002;184:4161–4167.
45. Cain AK, Boinett CJ, Barquist L, Dordel J, Fookes M et al. Morpho-
logical, genomic and transcriptomic responses of Klebsiella pneu-
moniae to the last-line antibiotic colistin. Sci Rep2018;8:9868.
46. Band VI, Crispell EK, Napier BA, Herrera CM, Tharp GK et al. Anti-
biotic failure mediated by a resistant subpopulation in Entero-
bacter cloacae. Nat Microbiol 2016;1:16053.
47. Makarova KS, Grishin NV. The Zn-peptidase superfamily: func-
tional convergence after evolutionary divergence. J Mol Biol 1999;
292:11–17.
48. Kooi C, Sokol PA. Burkholderia cenocepacia zinc metalloproteases
influence resistance to antimicrobial peptides. Microbiology 2009;
155:2818–2825.
49. Geisinger E, Isberg RR. Antibiotic modulation of capsular exopoly-
saccharide and virulence in Acinetobacter baumannii. PLoS Pathog
2015;11:e1004691–27.
50. Kenyon JJ, Hall RM. Variation in the complex carbohydrate bio-
synthesis loci of Acinetobacter baumannii genomes. PLoS One
2013;8:e62160.
51. Snitkin ES, Zelazny AM, Montero CI, Stock F, Mijares L, NISC
Comparative Sequence Program et al. Genome-wide recombina-
tion drives diversification of epidemic strains of Acinetobacter bau-
mannii. Proc Natl Acad Sci USA 2011;108:13758–13763.
52. Snitkin ES, Zelazny AM, Gupta J, Palmore TN, Murray PR, NISC
Comparative Sequencing Program et al. Genomic insights into the
fate of colistin resistance and Acinetobacter baumannii during
patient treatment. Genome Res 2013;23:1155–1162.
53. Beceiro A, Moreno A, Fernandez N, Vallejo JA, Aranda J et al. Bio-
logical cost of different mechanisms of colistin resistance and
their impact on virulence in Acinetobacter baumannii. Antimicrob
Agents Chemother 2014;58:518–526.
54. Bender RA. Regulation of the histidine utilization (hut) system in
bacteria. Microbiol Mol Biol Rev 2012;76:565–584.
55. Krell T, Lacal J, Busch A, Silva-Jimenez H, Guazzaroni ME et al.
Bacterial sensor kinases: diversity in the recognition of environ-
mental signals. Annu Rev Microbiol 2010;64:539–559.
56. Ramos JL, Martínez-Bueno M, Antonio J, Teran W, Watanabe K
et al. The TetR family of transcriptional repressors the TetR family
of transcriptional repressors. Microbiol Mol Biol Rev 2005;69:326–
356.
57. Piddock LJ. Clinically relevant chromosomally encoded multidrug
resistance efflux pumps in bacteria. Clin Microbiol Rev 2006;19:
382–402.
58. Cheah SE, Johnson MD, Zhu Y, Tsuji BT, Forrest A et al. Poly-
myxin resistance in Acinetobacter baumannii: genetic mutations
and transcriptomic changes in response to clinically relevant dos-
age regimens. Sci Rep 2016;6:26233.
59. Henry R, Crane B, Powell D, Deveson Lucas D, Li Z et al. The tran-
scriptomic response of Acinetobacter baumannii to colistin and
doripenem alone and in combination in an in vitro pharmacokinet-
ics/pharmacodynamics model. J Antimicrob Chemother 2015;70:
1303–1313.
60. Lin MF, Lin YY, Lan CY. Contribution of EmrAB efflux pumps to
colistin resistance in Acinetobacter baumannii. J Microbiol 2017;55:
130–136.
61. Ni W, Li Y, Guan J, Zhao J, Cui J et al. Effects of efflux pump inhib-
itors on colistin resistance in multidrug-resistant gram-negative
bacteria. Antimicrob Agents Chemother 2016;60:3215–3218.
Boinett et al., Microbial Genomics 2019;5
10
Five reasons to publish your next article with a Microbiology Society journal
1. The Microbiology Society is a not-for-profit organization.
2. We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3. Our journals have a global readership with subscriptions held in research institutions around
the world.
4. 80% of our authors rate our submission process as ‘excellent’ or ‘very good’.
5. Your article will be published on an interactive journal platform with advanced metrics.
Find out more and submit your article at microbiologyresearch.org.
